MediCool Technologies

What MediCool Technologies does

MediCool Technologies is a privately held, pre-revenue medical device company founded in 2015 and headquartered in Traverse City, Michigan. The company is developing a single investigational product, Cool Cardioversion — an implantable device that uses non-destructive thermal cooling of cardiac tissue to terminate atrial fibrillation (A-Fib). This mechanism is positioned as a painless alternative to conventional implantable cardioverter defibrillators (ICDs), which rely on electrical shocks that patients commonly describe as traumatic. Cool Cardioversion is classified by federal law as an investigational device limited to investigational use and has not yet received FDA approval; the company has completed proof-of-concept work and first-in-human feasibility cases.

The underlying technology uses thermal cooling rather than electrical current to restore normal heart rhythm, representing a novel architectural approach to cardioversion. The company is led by a clinical and commercial team anchored by Mayo Clinic electrophysiologists — CTO Dr. Paul Friedman (Chair of Cardiovascular Medicine at Mayo Clinic, 40+ patents, 300+ publications) and CMO Dr. Sam Asirvatham (professor of medicine at Mayo Clinic, 11+ patents in arrhythmia treatment) — alongside CEO Jeff Rynbrandt (19 years medical device commercialization experience) and CFO Peter von Alt (19 years of investment banking with $15B+ in IPOs advised).

MediCool's revenue model is medical-device hardware sales to electrophysiologists, cardiologists, and hospital cardiology departments in the United States, distributed through a direct enterprise field-sales motion post-FDA approval. The company is pre-revenue with no current paying customers; near-term revenue is contingent on regulatory clearance. To date, MediCool has been funded by two National Science Foundation grants (2016: $225K; 2018: $671K) and a 2023 investment from Michigan Rise, the VC subsidiary of the Michigan State University Research Foundation, with primary capital deployment toward R&D, clinical studies, and FDA submission preparation.

Name

MediCool Technologies

Legal name

MediCool Technologies

Website

https://medicooltech.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

MediCool Technologies is a pre-revenue medical device company developing Cool Cardioversion, an investigational implantable device that uses thermal cooling to painlessly terminate atrial fibrillation, targeting electrophysiologists and hospital cardiology departments pending FDA approval.

Ownership category

akta.pro rank

Product category

Cardiac Rhythm Management Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiac Rhythm Management (Pacemakers, ICDs, CRT) (HLAHAFAC)

Keywords

• Cardiac medical devices
• Atrial fibrillation treatment
• Implantable cardioverter devices
• Thermal cardiac therapy
• Electrophysiology devices

Headquarters

HQ city

Rochester

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: As a medical device company developing an implantable cardioversion device, MediCool will generate revenue through the sale of its Cool Cardioversion device to healthcare providers and hospital systems. The company is pre-revenue as the device is still in development and undergoing clinical studies for FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

MediCool Technologies is developing Cool Cardioversion™, an investigational implantable medical device that uses non-destructive thermal cooling of cardiac tissue to painlessly terminate atrial fibrillation and other dangerous cardiac arrhythmias. The device is designed as an alternative to traditional implantable cardioverter defibrillators (ICDs) that deliver painful electrical shocks, intended for use by electrophysiologists, cardiologists, and hospital cardiology departments at the point of care. The product is currently pre-clinical and in early first-in-human clinical studies pending FDA approval.

Product overview

MediCool Technologies is a single-product medical device company developing Cool Cardioversion™ — an investigational implantable cardioversion device that uses thermal cooling technology rather than electrical shocks to terminate atrial fibrillation. The device is designed to painlessly restore normal heart rhythm at the point of care, offering an alternative to conventional ICDs. The product is currently in pre-clinical and early human clinical trial stages, pending FDA approval.

Differentiator

Problem solved

Functional benefit

Brands

• Cool Cardioversion: A painless thermal therapy device that non-destructively cools cardiac tissue to terminate atrial fibrillation without the painful electrical shocks used by traditional ICDs.

Quantifiable outcome

• The company has demonstrated feasibility in pre-clinical and first in human cases

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Michigan State UniversityminorStrategic or Co-development PartnerMediCool has a partnership with Michigan State University through Michigan Rise's ecosystem. The partnership with Michigan Rise and MSU helps fuel continued innovation in the company's thermal cooling technology for cardiac arrhythmias.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Medtronic: Medtronic is the global leader in cardiac rhythm management and the dominant manufacturer of implantable cardioverter defibrillators (ICDs). MediCool's Cool Cardioversion is positioned as an alternative to traditional ICD shock therapy, making Medtronic the most relevant incumbent competitor with overlapping electrophysiology customers and hospital relationships.
• Abbott: Abbott is a leading player in cardiac rhythm management with its ICD and CRT-D portfolio, as well as electrophysiology tools. Its installed base, sales infrastructure, and EP lab relationships make it a primary competitor for any next-generation AFib termination device, including Cool Cardioversion.
• Boston Scientific: Boston Scientific is a major CRM and electrophysiology player with a deep portfolio of ICDs, ablation catheters, and EP lab solutions. It targets the same electrophysiologists and cardiology departments as MediCool, and would be a likely competitor in any painless or alternative cardioversion modality.

Direct peers

• Biotronik: Biotronik is a CRM specialist that manufactures ICDs and pacemakers and competes directly in the implantable cardioverter defibrillator category. As a focused CRM company targeting electrophysiologists, Biotronik is closely comparable to MediCool's positioning in the ICD-alternative space.

Emerging players

• AtriCure: AtriCure develops surgical ablation and left atrial appendage management devices for atrial fibrillation, addressing the same patient population as MediCool's Cool Cardioversion. Although it uses a different modality (surgical cryo/radiofrequency ablation), it competes for EP and cardiology procedural spend on AFib treatment.
• Adagio Medical: Adagio Medical is developing cryoablation technologies for atrial fibrillation, including pulsed and ultra-low-temperature cryo catheters. Although a catheter-based approach differs from MediCool's implantable thermal device, both leverage cooling energy to terminate AFib and target the same electrophysiology customer base.
• CardioFocus: CardioFocus develops laser balloon ablation systems for treating atrial fibrillation. It overlaps with MediCool in treating AFib with an alternative energy modality (laser vs. thermal cooling) and competes for electrophysiology lab procedure volumes.
• Acutus Medical: Acutus Medical develops electrophysiology mapping and ablation technologies for arrhythmia diagnosis and treatment. While focused on mapping and catheter ablation rather than cardioversion, it targets the same electrophysiology specialists and competes for AFib management procedure budgets.
• Stereotaxis: Stereotaxis provides robotic navigation systems for cardiac ablation and other EP procedures. While its technology (robotic magnetic navigation) differs from MediCool's thermal cardioversion approach, it serves the same electrophysiology customers and increasingly competes for advanced AFib treatment workflows.
• CryoLife (now Artivion): Artivion (formerly CryoLife) has historic expertise in cryopreservation and cryobiology and is active in cardiac surgery and vascular technologies relevant to cryothermal cardiac therapies. While it focuses on cardiac surgery and tissue preservation rather than implantable cardioversion, its cryothermal capabilities are technically adjacent to MediCool's cooling-based cardioversion approach.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/CoolAFib
• LinkedInlinkedin.com/company/medicool-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MediCool Technologies